Antiepileptic Drugs Tied to Incident Parkinson Disease

WEDNESDAY, Jan. 4, 2023 (HealthDay News) -- Antiepileptic drugs are associated with incident Parkinson disease, according to a study published online Dec. 27 in JAMA Neurology.
Daniel Belete, M.B.Ch.B., from Queen Mary University of London, and colleagues investigated the association between antiepileptic drugs and incident Parkinson disease using data from 1,433 individuals with a Parkinson disease diagnosis and 8,598 matched controls. Routinely collected prescription data derived from primary care were used to define exposure to antiepileptic drugs (carbamazepine, lamotrigine, levetiracetam, and sodium valproate).
The researchers observed an association between antiepileptic drug prescriptions and incident Parkinson disease (odds ratio, 1.80) in a dose-response fashion, with a trend for a greater number of prescription issues and multiple antiepileptic drugs being associated with a greater risk for Parkinson disease.
"To the best of our knowledge, this is the first observational study to investigate a range of antiepileptic drugs and their association with incident Parkinson disease. As such, it sets the scene and highlights the need for further work to corroborate our findings in other large data sets because these findings could have important implications for clinical decision-making," the authors write. "The underlying reasons for an association between antiepileptic drugs and Parkinson disease should be further explored."
Two authors disclosed financial ties to the pharmaceutical industry.
Related Posts
Limiting TV to Under 1 Hour a Day Could Slash Heart Disease Rates: Study
WEDNESDAY, May 25, 2022 (HealthDay News) -- It's tempting to binge-watch TV...
Cómo hablar con los niños sobre la guerra en Ucrania
VIERNES, 11 de marzo de 2022 (HealthDay News) -- Si la invasión rusa en Ucrania...
Mindfulness Training, Exercise No Aid for Cognitive Function
WEDNESDAY, Dec. 21, 2022 (HealthDay News) -- Neither mindfulness training nor...
Un panel de la FDA se muestra escéptico sobre un controversial fármaco para la ELA antes de una votación
MARTES, 6 de septiembre de 2022 (HealthDay News) -- Un panel de la...
